Overexpression and hyperactivation of the type I insulinlike growth factor receptor (IGF-IR) has been observed in human breast tumor biopsies. In addition, in vitro studies indicate that overexpression of IGF-IR is sufficient to transform cells such as mouse embryo fibroblasts and this receptor promotes proliferation and survival in breast cancer cell lines. To fully understand the function of the IGF-IR in tumor initiation and progression, transgenic mice containing human IGF-IR under a doxycyclineinducible MMTV promoter system were generated. Administration of 2 mg/ml doxycycline in the animals' water supply beginning at 21 days of age resulted in elevated levels of IGF-IR in mammary epithelial cells as detected by Western blotting and immunohistochemistry. Whole mount analysis of 55-day-old mouse mammary glands revealed that IGF-IR overexpression significantly impaired ductal elongation. Moreover, histological analyses revealed multiple hyperplasic lesions in the mammary glands of these 55-day-old mice. The formation of palpable mammary tumors was evident at approximately 2 months of age and was associated with increased levels of IGF-IR signaling molecules including phosphorylated Akt, Erk1/Erk2 and STAT3. Therefore, these transgenic mice provide evidence that IGF-IR overexpression is sufficient to induce mammary epithelial hyperplasia and tumor formation in vivo and provide a model to further understand the function of IGF-IR in mammary epithelial transformation.
Introduction
The insulin-like growth factor (IGF) family consists of two ligands, IGF-I and IGF-II, at least two receptors, insulin-like growth factor receptor (IGF-IR) and IGF-IIR, and six high affinity binding proteins, IGFBP-1 to IGFBP-6 (Wetterau et al., 1999; Werner and Le Roith, 2000) . The type I IGF receptor (IGF-IR) is primarily responsible for the mitogenic and antiapoptotic actions of the IGFs while the IGF-IIR has been implicated in IGF-II degradation. The IGF-IR is a tetramer comprised of two extracellular subunits and two transmembrane subunits. Binding of IGF-I or IGF-II to the extracellular portion of the receptor triggers autophosphorylation of the subunits and activation of the tyrosine kinase domain. This phosphorylation permits the activation of intracellular signaling such as the Erk1/ 2 and Akt pathways that induce cell proliferation and inhibit apoptosis (Marte and Downward, 1997; Cardone et al., 1998; Muise-Helmericks et al., 1998; Richards et al., 1998; Baserga, 1999; Surmacz, 2000; Adams et al., 2004) .
Expression of IGF family members are often altered in breast cancer (Papa et al., 1993; Ellis et al., 1994; Helle and Lonning, 1996; Surmacz, 2000) . IGF-II mRNA and protein were detected in 97% of the invasive ductal carcinoma cases examined, whereas IGF-II expression in normal mammary epithelium is very low or undetectable (Giani et al., 1996) . Elevated levels of serum IGF-I and reduced levels of serum IGFBP-3 have been associated with an increased relative risk for breast cancer especially in premenopausal women under the age of 50 years (Hankinson et al., 1998) . Finally, a direct association between IGF-I and IGF-II overexpression and mammary tumorigenesis has been established in transgenic mice (Bates et al., 1995; Pravtcheva and Wise, 1998; Hadsell et al., 2000) .
IGF-IR expression is present in human breast cancer cell lines and in breast cancer biopsy specimens. IGF-IR levels have been found to be elevated as high as 14-fold in human breast cancer tissue and hyperphosphorylation of the IGF-IR has also been reported in breast cancer biopsies (Surmacz, 2000) . High IGF-IR levels in primary breast tumors have been associated with shorter disease-free survival but not all studies agree on the prognostic value of IGF-IR (Turner et al., 1997; Resnik et al., 1998; Surmacz et al., 1998; Surmacz, 2000) . A recent study has shown that overexpression of a constitutively active IGF-IR driven by the mouse mammary tumor virus (MMTV) promoter results in the formation of mammary adenocarcinomas (Carboni et al., 2005) . While this study illustrates the oncogenic potential of IGF-IR overexpression in the mammary epithelium, the use of a constitutively active receptor circumvents the complex ligand-receptor dynamics of the native receptor that occurs in vivo.
In this paper we describe a transgenic animal model that overexpresses the wild-type (WT) IGF-IR in a doxycycline inducible manner. Our findings indicate that IGF-IR overexpression is sufficient to induce mammary epithelial hyperplasia and tumors in vivo. Therefore, IGF-IR is a critical regulator of mammary epithelial transformation and these transgenic mice provide a model to delineate the exact mechanism through which IGF-IR overexpression mediates mammary tumor initiation and progression.
Results

Analysis of transgene expression in MTB-IGFIR mice
Expression of IGF-IR was induced with 2 mg/ml doxycycline in the drinking water beginning at 21 days of age in all animals utilized in this paper. This concentration of doxycycline has previously been demonstrated to induce near-maximal expression of the rtTA in the MTB mice (Gunther et al., 2002) . Mammary tissue from MTB-IGFIR1 mice treated with doxycycline for either 21 days or 34 days contained elevated levels of IGF-IR compared to MTB, TRE-IGFIR1 and WT-treated mice (Figure 1a ). Immunohistochemistry indicated that doxycycline-treated WT mice contained low levels of endogenous IGF-IR in the mammary ducts and terminal end buds (Figure 1b and c) . In contrast, high levels of IGF-IR were evident in the mammary ducts and terminal end buds of doxycyclinetreated MTB-IGFIR1 mice (Figure 1d and e). Elevated levels of IGF-IR were not observed in other tissues as determined by immunohistochemistry (data not shown).
Quantification of proliferating cell nuclear antigen (PCNA) immunohistochemistry on mammary glands from 55-day-old mice revealed a significant increase in the percentage of PCNA-positive mammary epithelial cells in MTB-IGFIR1 transgenic mice compared to mice with normal IGF-IR levels (pooled data from single transgenic mice, WT mice and nondoxycycline-treated MTB-IGFIR1 mice) (Figure 1f ).
IGF-IR overexpression impairs mammary ductal development
Mammary glands from 55-day-old mice (treated with doxycycline beginning at 21 days of age) revealed that mammary development was highly abnormal in both MTB-IGFIR1 and MTB-IGFIR2 transgenics (Figure 2i and j) compared to MTB (Figure 2c and d) or TRE-IGFIR1 (Figure 2e and f) single transgenics and WT (Figure 2a and b) doxycycline-treated mice. In doxycycline-treated MTB-IGFIR mice (both line1 and line2), elongation of the ductal structure was delayed and in some cases remained behind the lymph node in contrast to control mice in which the ductal structure had almost completely filled the mammary fat pad.
In WT, doxycycline-treated mice, terminal end buds (TEBs) were easily identified at the growing end of the mammary glands. However, epithelial hyperplasia in the doxycycline-treated MTB-IGFIR transgenic mice rendered it difficult to determine whether IGF-IR overexpression altered the number of TEBs that developed. The number of ducts was also difficult to quantify due to the presence of hyperplasia (Supplementary Figure 1 ).
IGF-IR overexpression induces mammary epithelial hyperplasia and tumor development
Multiple hyperplastic nodules were observed in hematoxylin and eosin stained sections of all 55-day-old, doxycycline-treated MTB-IGFIR1 mice examined (n ¼ 6). Multiple hyperplastic nodules were also observed in a 55-day-old, doxycycline-treated MTB-IGFIR2 mouse. A cohort of MTB-IGFIR mice were maintained on doxycycline for an extended period of time and all of these MTB-IGFIR mice developed palpable mammary tumors with an average latency of 78 days in line 1 (n ¼ 5) and 71 days of age in line 2 (n ¼ 5). MTB-IGFIR1 mice typically developed one or two palpable tumors in the first or second/third mammary glands with hyperplastic nodules evident in histologic sections of the other mammary glands. One mouse from line 1 developed multiple mammary tumors while all five MTB-IGFIR2 mice, examined to date, have developed multiple mammary tumors (Table 1) . Macroscopically the tumors varied in appearance from large, blood/fluid-filled cysts to white, solid masses.
Mammary tumors in the MTB-IGFIR1 transgenic mice maintained high levels of IGF-IR expression and were highly proliferative. Staining for smooth muscle actin, a marker of myoepithleial cells, revealed a continuous layer of myoepithelial cells around the entire perimeter of the majority of the tumors. However, some tumors lacked smooth muscle actin staining and appeared to be locally invasive. Levels of the adhesion molecule E-cadherin in the tumors were similar to normal mammary epithelial ducts . E-cadherin staining was still present even in areas where the tumor appeared to be invading the local adipose tissue (Supplementary Figure 2) .
Histology of MTB-IGFIR mammary tumors
Small mammary lesions from doxycycline-treated MTB-IGFIR1 transgenics were relatively homogenous and were primarily composed of solid sheets of tumor cells with sparse stroma (Figure 3a and b) . These tumors are similar in appearance to tumors found in erbB2 transgenic mice (Rosner et al., 2002) . In contrast, larger tumors were more heterogeneous in appearance. While some of the larger tumors also resembled those induced by transgenic overexpression of erbB2 (Figure 3c ), other tumors, or even regions within the same tumor, displayed an increase in stroma between the tumors cells (Figure 3d-g ). Other tumors displayed features of adenosquamous carcinoma (Figure 3h ), adenomyoepithelioloma ( Figure 3i ) and glandular adenocarcinoma with abundant secretion (Figure 3j (Figure 5a and c) . Some of the small hyperplastic nodules exhibited ER and PR expression, however, at reduced levels compared to that observed in mature ducts (Figure 5b and d) .
Expression of signaling molecules associated with MTB-IGFIR mammary tumors Western blotting revealed that tumors from MTB-IGFIR1 transgenics contained increased levels of IGF-IR and IGF-IR tyrosine phosphorylation (Figure 6 ) compared to controls. Elevated levels of phosphorylated Akt, Erk1/2 and STAT3 as well as nonphosphorylated STAT3 levels were also observed in tumor tissue compared to controls. No changes in the levels of p38MAPK or Stat5 activation were seen and levels of phosphorylated JNK/SAPK and STAT6 could not be detected (data not shown).
Discussion
The present study describes the generation of transgenic mice that display mammary epithelial-specific expression of IGF-IR in a doxycycline-inducible manner. Our findings demonstrate that IGF-IR is a critical regulator of mammary ductal development and that aberrant expression of IGF-IR is sufficient to induce mammary epithelial hyperplasia and tumor formation.
Knockout and transgenic mouse models have previously shown that the IGF system is essential for normal pubertal mammary gland development. Loss of IGF-I or IGF-IR expression in the mammary gland has been shown to result in a decrease in the number of TEBs, ductal branch points and ductal elongation (Ruan and Kleinberg, 1999; Bonnette and Hadsell, 2001; Richards et al., 2004) . Delayed ductal growth and a reduction in TEB number was also observed in a transgenic mouse model overexpressing a constitutively activated IGF-IR in the mammary epithjleium (Carboni et al., 2005) .
To determine the effect of overexpression of WT IGF-IR on pubertal mammary development IGF-IR expression was induced following weaning at 21 days of age. Mammary gland development in 55-day-old MTB-IGFIR mice was severely disrupted exhibiting a delay in ductal elongation and an apparent increase in ductal side branching compared to control mice. This phenotype is similar to that observed in mice expressing a constitutively active IGF-IR in the mammary epithelium (Carboni et al., 2005) . However, ductal branching was difficult to quantify in our transgenics due to the extensive epithelial hyperplasia. The development of hyperplasia at the leading edge of the growing mammary gland in MTB-IGFIR mice, where TEBs are present, also did not allow us to accurately determine the effect of IGF-IR overexpression on TEB number. Therefore, our results support previous studies indicating that IGF-IR signaling must be tightly regulated for normal mammary development to take place.
We have also demonstrated that IGF-IR overexpression is a rapid inducer of mammary epithelial hyperplasia as hyperplastic nodules were observed in all 55-day-old doxycycline-treated MTB-IGFIR transgenics and palpable mammary tumors development at approximately 10-11 weeks of age. This is the first in vivo demonstration that overexpression of WT IGF-IR is sufficient to induce mammary epithelial transformation. This observation is consistent with the ability of IGF-IR to transform cells in culture (Rubini et al., 1997; Butler et al., 1998) .
It is also interesting to note that overexpression of WT IGF-IR starting at 21 days of age our IGF-IR transgenic mice induced mammary tumors with approximately the same latency as the transgenic mice overexpressing an activated version of IGF-IR, presumably since embryonic development (Carboni et al., 2005) . Thus, overexpression of the WT IGF-IR is sufficient for mammary epithelial transformation and possesses a similar capacity to transform mammary epithelium as a constitutively active IGF-IR. The IGF-IR also appears to be as effective or more effective at transforming mammary epithelial cells than erbB2 as overexpression of WT IGF-IR induced palpable tumors by 10-11 weeks of age while overexpression of WT and constitutively active erbB2 resulted in the development of palpable tumors at 29 weeks (Guy et al., 1992) and 13 weeks (Muller et al., 1988) , respectively.
Transgene-induced mouse mammary tumors can typically be categorized into two groups based on their pathology. One group contains erbB2/ras pathway oncogenes and these form solid, nodular tumors with scanty stroma and lack myoepithelial cells an squamous metaplasia (Rosner et al., 2002) . The other group contains Wnt pathway oncogenes that form tumors containing ductular architecture, considerable stroma with significant lymphocytic infiltration and frequently differentiate in to acinar, squamous and myoepithelial components (Rosner et al., 2002) . Histology and cytokeratin immunohistochemistry revealed that tumors induced by IGF-IR contained characteristics of both erbB2 and Wnt pathway oncogenes. Some tumors formed solid nodules containing cytokeratin 8 and 18 similar to erbB2 pathway tumors while some of the larger, more advanced IGF-IR induced tumors contained cytokeratin 5 and cytokeratin 14 positive cells indicative of basal cells and myoepithelial cells frequently observed in Wnt pathway induced mammary tumors. Therefore, although the IGF-IR induced tumors share a number of features with erbB2/ras tumors, they may not strictly adhere to the pathway pathology designations (Rosner et al., 2002) .
In humans, breast tumors with a mixed lumenal and basal phenotype or a pure basal phenotype, have a poorer prognosis than breast tumors with a pure lumenal phenotype (Abd El-Rehim et al., 2004) . Thus, larger MTB-IGFIR1 mammary tumors have characteristics of aggressive tumors yet, despite evidence of local invasion, metastatic spread has not been detected. Breast tumor progression has been associated with the downregulation of the cell-cell adhesion molecule E-cadherin (Cowin et al., 2005) . MTB-IGFIR1 mammary tumors retained high expression of E-cadherin even in areas of local invasion. This finding suggests that additional genetic events, such as loss of E-cadherin expression, are required for metastatic spread of tumor cells.
Approximately 70% of human breast cancers are ERpositive (Althuis et al., 2004) and expression of ER is an important predictor of response to anti-estrogen therapy (Early Breast Cancer Trialists' Collaborative Group, 1998). Breast tumors lacking ER or PR expression are associated with poor histological differentiation and to some extent a worse outcome (Lapidus et al., 1998) . In MTB-IGFIR1 mice expression of ER and PR was low or undetectable in the larger tumors but some of the smaller hyperplastic nodules contained ER-and PRpositive cells. Thus, large tumors in the MTB-IGFIR1 mice provide a model of ER-and PR-negative breast cancer.
Some of the downstream molecules that may mediate IGF-IR-induced cell transformation include Akt, Erk1/ 2, and STAT3 as elevated levels of the phosphorylated forms of these proteins were observed in the MTB-IGFIR1 mammary tumors compared to normal mammary glands. Erk1/2 and Akt activation following stimulation of IGF-IR have been well documented and have been shown to mediate cell proliferation, and inhibit apoptosis in a number of cell types including breast cancer cells (Santen et al., 2002; Kumar and Hung, 2005) . While Akt and Erk1/Erk2 are common downstream mediators of IGF-IR, there is limited data concerning activation of STAT proteins by IGF-IR (Takahashi et al., 1999; Zong et al., 2000; Zhang et al., 2006) . STATs are a family of cytoplasmic transcription factors that typically mediate cytokine and growth factor signaling and in turn, regulate proliferation, apoptosis, differentiation and motility (Yu and Jove, 2004) . Phosphorylation of STAT proteins results in dimerization followed by translocation into the nucleus where they bind to DNA and regulate gene transcription. Activated STAT3 promotes breast cancer cell proliferation (Li and Shaw, 2002) , and inhibits apoptosis . In human breast cancer tissue, elevated cytoplasmic and nuclear STAT3 (Berclaz et al., 2001) as well as nuclear tyrosine phosphorylated STAT3 (Diaz et al., 2006) has been reported. STAT5 has also been implicated in breast cancer but the levels of phosphorylated STAT5 were not significantly elevated in our model.
To date, only one other transgenic mouse overexpressing the type I IGF receptor has been described (Carboni et al., 2005) . In this mouse a fusion protein representing the extracellular sequence of CD8a´gene and residues 964-1367 of the human IGF-IR gene was overexpressed using the MMTV promoter (Carboni et al., 2005) . This fusion protein produced a constitutively active IGF-IR. Both models demonstrated that overexpression of IGF-IR impaired mammary ductal development and induced mammary tumors thus indicating the importance of IGF-IR in these processes. The main differences in our MTB-IGFIR transgenics are the use of human WT IGF-IR and the inducible nature of IGF-IR in MTB-IGFIR mice.
The MTB-IGFIR transgenic mice should provide an invaluable preclinical model for the evaluation of emerging anti-IGF-IR therapies. The MTB-IGFIR mice could be used to examine molecules critical for the initial hyperplastic events as well as targets involved in the later stages of mammary tumorigenesis. In addition, the MTB-IGFIR mice can be utilized to understand how IGF-IR overexpression induces mammary epithelial transformation and examine interactions between IGF-IR and other hormones and growth factors, in vivo.
Materials and methods
Mice MTB mice were provided by Dr L Chodosh (University of Pennsylvania, Philadelphia, PA, USA) and are described in Gunther et al. (2002) . TRE-IGFIR transgenic mice were generated by cloning the full-length human IGF-IR cDNA (provided by Dr R Baserga, Kimmel Cancer Institute, Philadelphia, PA, USA) downstream of the pTRE2 vector (Clontech, Palo Alto, CA, USA). The TRE-IGFIR construct was microinjected at a concentration of 1 ng/ml into the pronuclei of zygotes from FVB mice and microinjected zygotes were transferred to pseudopregnant FVB females. Four independent TRE-IGFIR transgenic mice were generated (TRE-IGFIR1-4). The MTB transgenic mice were then mated with TRE-IGFIR transgenic mice producing the desired double transgenic mice designated as MTB-IGFIR.
For doxycycline treatment, 2 mg/ml of doxycycline (Sigma, St Louis, MO, USA) was added to the animals' drinking supply that also contained 5% sucrose (Sigma, St Louis, MO, USA) beginning at 21 days of age. Water was protected from light and changed every 3-4 days. Two independent lines of TRE-IGFIR transgenic mice (TRE-IGFIR1 and TRE-IGFIR2) were shown to overexpress IGF-IR protein in mammary epithelial cells when coexpressed with the MTB transgene (MTB-IGFIR1 and MTB-IGFIR2) and treated with doxycycline. Mice were maintained following the guidelines of the Canadian Council on Animal Care.
Whole mounts and immunohistochemistry
Mammary whole mounts were performed using the method described in Moorehead et al. (2001) Immunohistochemistry was performed as previously described (Linnerth et al., 2005) . Primary antibodies were used at the following dilutions, 1:25 for anti-ER (Beckman Coulter Immunotech, Miami, FL, USA), 1:50 for anti-IGF-IR (R&D Systems Inc., Minneapolis, MN, USA), anti-cytokeratin 18 (Research Diagnostics Inc., Flanders, NJ, USA), 1:100 for of anti-smooth muscle actin (RDI Inc., Flanders, NJ, USA), anti-E-cadherin (Cell Signal Technology, Beverly, MA, USA), anti-PR (Lab Vision, Fremont, CA, USA), anti-cytokeratin 5 (Abcam, Cambridge, MA, USA), anti-cytokeratin 7 (Santa Cruz Technologies, Santa Cruz, MA, USA), anti-cytokeratin 8 (Fitzgerald Industries International Inc., Concord, MA, USA), cytokeratin 14 (Abcam, Cambridge, MA, USA), and 1:3000 for anti-PCNA (Sigma, St Louis, MO,USA). Primary antibodies were detected using a 1:200 dilution of the appropriate secondary and Sigma Fast 3,3 0 -diaminobenzidine tablets (Sigma, St Louis, MO, USA).
Western blotting
Western blotting was performed as previously described (Moorehead et al., 2001) . Primary antibodies included a 1:1000 of anti-IGF-IR (R&D Systems Inc., Minneapolis, MN, USA), anti-phospho-IGFIR, anti-phospho-Akt, antiAkt, anti-phospho-Erk1/Erk2, anti-Erk1/Erk2, anti-phosphop38MAPK, anti-p38MAPK, anti-phospho-Stat3, anti-Stat3 (Cell Signal Technology, Beverly, MA, USA) and anti-tubulin (Santa Cruz Technologies, Santa Cruz, CA, USA) diluted in 5% BSA in TBST. Protein levels were detected using a 1:2000 dilution of the appropriate secondary antibody (Cell Signal Technology, Beverly, MA, USA) and Western Lightning Chemiluminescence substrate (Perkin-Elmer, Wellesley, MA, USA). Images were captured and quantified on a FluorChem 9900 gel documentation systems (Alpha Innotech, San Leandro, CA, USA) imaging system.
